GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: Results from the New England bladder cancer study and NAT2 meta-analysis

L. E. Moore, D. R. Baris, J. D. Figueroa, M. Garcia-Closas, M. R. Karagas, M. R. Schwenn, A. T. Johnson, J. H. Lubin, D. W. Hein, C. L. Dagnall, J. S. Colt, M. Kida, M. A. Jones, A. R. Schned, S. S. Cherala, S. J. Chanock, K. P. Cantor, D. T. Silverman, N. Rothman

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: Results from the New England bladder cancer study and NAT2 meta-analysis'. Together they form a unique fingerprint.

Medicine & Life Sciences